What are the key results and implications of the CONVERT trial that supported the FDA approval of amikacin liposome inhalation suspension; and what percentage of treatment refractory patients achieved microbial conversion?

What are the key results and implications of the CONVERT trial that supported the FDA approval of amikacin liposome inhalation suspension; and what percentage of treatment refractory patients achieved microbial conversion?

What are the key results and implications of the CONVERT trial that supported the FDA approval of amikacin liposome inhalation suspension; and what percentage of treatment refractory patients achieved microbial conversion?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone